LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Appoints ophthalmology development leader Spivey to Board of Directors
Uncategorized
Analysis: Lucentis may be more cost-effective than Eylea for DME
VIENNA — A cost-effectiveness analysis based on Protocol T results found considerably higher costs and minimal gain in quality-adjusted life-years with Eylea compared with Lucentis for the treatment of diabetic macular edema, leading to the conclusion that Lucentis may be more cost-effective.“We used the Markov model, which takes visual acuity and divides it into groups from best to worst vision, and then we used an algorithm to sort these visual acuities into visual impairment costs and QALYs,” Nancy Holekamp, MD, said at the American Society of Retina Specialists meeting.
Abbott iDesign Advanced WaveScan Features Space Telescope Technology (VIDEO)
Abbott is unveiling a new LASIK system, just approved by the FDA, that produces high resolution scans of the human eye with levels of detail previously unavailable in clinical systems. The iDesign Advanced WaveScan Studio System takes 1,200 readings of the eye within a three second scan. It measures parameters such as the shape of the [&hellip (Read more...)
Squalamine Shows Promise in Retinal Vein Occlusion
The combination of topical squalamine and intravitreal ranibizumab appears to boost visual acuity more rapidly than ranibizumab alone in patients with retinal vein occlusion, a small study shows. Medscape Medical News
Uncategorized
Pyron Award lecture focuses on optogenetics as vision restoration strategy
VIENNA — The Pyron Award lecture at the American Society of Retina Specialists meeting focused on optogenetics, an exciting advancement with the possibility of restoring vision in blind patients with inherited retinal degeneration. Gary W. Abrams, MD, explained that the concept, first described in 2005 by Boyden and colleagues, consists of the introduction of the genetic material of a light-sensitive protein into the cell membrane of light-insensitive retinal cells to effectively turn them into photoreceptors.
Uncategorized
Valeant to acquire Amoun Pharmaceutical
Valeant Pharmaceuticals International announced in a press release that it has entered into a definitive agreement to purchase Mercury (Cayman) Holdings, the holding company of Amoun Pharmacuetical, for approximately $800 million in addition to conting…